Reversal of autism-like behaviors and metabolism in adult mice with single-dose antipurinergic therapy
JC Naviaux, MA Schuchbauer, K Li, L Wang… - Translational …, 2014 - nature.com
Autism spectrum disorders (ASDs) now affect 1–2% of the children born in the United States.
Hundreds of genetic, metabolic and environmental factors are known to increase the risk of …
Hundreds of genetic, metabolic and environmental factors are known to increase the risk of …
Antipurinergic therapy corrects the autism-like features in the poly (IC) mouse model
RK Naviaux, Z Zolkipli, L Wang, T Nakayama… - PloS one, 2013 - journals.plos.org
Background Autism spectrum disorders (ASDs) are caused by both genetic and
environmental factors. Mitochondria act to connect genes and environment by regulating …
environmental factors. Mitochondria act to connect genes and environment by regulating …
Effects of single-dose antipurinergic therapy on behavioral and molecular alterations in the valproic acid-induced animal model of autism
MM Hirsch, I Deckmann, J Santos-Terra, GZ Staevie… - …, 2020 - Elsevier
Autism spectrum disorder (ASD) is characterized by deficits in communication and social
interaction, restricted interests, and stereotyped behavior. Environmental factors, such as …
interaction, restricted interests, and stereotyped behavior. Environmental factors, such as …
Pathophysiological studies of monoaminergic neurotransmission systems in valproic acid-induced model of autism spectrum disorder
HY Kuo, FC Liu - Biomedicines, 2022 - mdpi.com
Autism spectrum disorder (ASD) is a neurodevelopmental disorder with complex etiology.
The core syndromes of ASD are deficits in social communication and self-restricted interests …
The core syndromes of ASD are deficits in social communication and self-restricted interests …
Antipurinergic therapy corrects the autism-like features in the Fragile X (Fmr1 knockout) mouse model
JC Naviaux, L Wang, K Li, AT Bright, WA Alaynick… - Molecular autism, 2015 - Springer
Background This study was designed to test a new approach to drug treatment of autism
spectrum disorders (ASDs) in the Fragile X (Fmr1) knockout mouse model. Methods We …
spectrum disorders (ASDs) in the Fragile X (Fmr1) knockout mouse model. Methods We …
Metabolic and behavioral features of acute hyperpurinergia and the maternal immune activation mouse model of autism spectrum disorder
Z Zolkipli-Cunningham, JC Naviaux, T Nakayama… - PloS one, 2021 - journals.plos.org
Since 2012, studies in mice, rats, and humans have suggested that abnormalities in
purinergic signaling may be a final common pathway for many genetic and environmental …
purinergic signaling may be a final common pathway for many genetic and environmental …
[HTML][HTML] Molecular pathology and pharmacological treatment of autism spectrum disorder-like phenotypes using rodent models
HY Kuo, FC Liu - Frontiers in cellular neuroscience, 2018 - frontiersin.org
Autism spectrum disorder (ASD) is a heterogeneous neurodevelopmental disorder with a
high prevalence rate. The core symptoms of ASD patients are impaired social …
high prevalence rate. The core symptoms of ASD patients are impaired social …
Developmental disruption of amygdala transcriptome and socioemotional behavior in rats exposed to valproic acid prenatally
Background The amygdala controls socioemotional behavior and has consistently been
implicated in the etiology of autism spectrum disorder (ASD). Precocious amygdala …
implicated in the etiology of autism spectrum disorder (ASD). Precocious amygdala …
Targeting anandamide metabolism rescues core and associated autistic-like symptoms in rats prenatally exposed to valproic acid
M Servadio, F Melancia, A Manduca, A Di Masi… - Translational …, 2016 - nature.com
Autism spectrum disorders (ASD) are characterized by altered sociability, compromised
communication and stereotyped/repetitive behaviors, for which no specific treatments are …
communication and stereotyped/repetitive behaviors, for which no specific treatments are …
Low‐dose suramin in autism spectrum disorder: a small, phase I/II, randomized clinical trial
RK Naviaux, B Curtis, K Li, JC Naviaux… - Annals of Clinical …, 2017 - Wiley Online Library
Objective No drug is yet approved to treat the core symptoms of autism spectrum disorder
(ASD). Low‐dose suramin was effective in the maternal immune activation and Fragile X …
(ASD). Low‐dose suramin was effective in the maternal immune activation and Fragile X …